Loading
A phase 3 trial of Toripalimab, Gemcitabine, Cisplatin and Carboplatin in bladder & urothelial cancer, run by RemeGen Co., Ltd., now recruiting.
A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma is a phase 3 interventional study registered as NCT05302284 by RemeGen Co., Ltd., with 452 participants planned, started 2022-06-14 and due to reach its primary completion in 2026-12-31. Interventions recorded: RC48-ADC, Toripalimab, Gemcitabine, Cisplatin and Carboplatin.
Shares Muscle-invasive and advanced bladder cancer, Toripalimab, Gemcitabine, Bladder & urothelial cancer and the tag pipeline.
Shares RemeGen, Muscle-invasive and advanced bladder cancer, Gemcitabine, Bladder & urothelial cancer and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Gemcitabine, Bladder & urothelial cancer, Cisplatin and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Gemcitabine, Bladder & urothelial cancer, Cisplatin and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Gemcitabine, Bladder & urothelial cancer, Cisplatin and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Gemcitabine, Bladder & urothelial cancer, Cisplatin and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Gemcitabine, Bladder & urothelial cancer, Cisplatin and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Toripalimab, Bladder & urothelial cancer, Immune checkpoint inhibitors and the tag pipeline.